- Home
- ALX vs SANA Comparison
ALX vs SANA Comparison
Compare ALX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- SANA
- Stock Information
- Founded
- ALX 1928
- SANA 2018
- Country
- ALX United States
- SANA United States
- Employees
- ALX N/A
- SANA N/A
- Industry
- ALX Real Estate Investment Trusts
- SANA Medicinal Chemicals and Botanical Products
- Sector
- ALX Real Estate
- SANA Health Care
- Exchange
- ALX Nasdaq
- SANA Nasdaq
- Market Cap
- ALX 1.2B
- SANA 983.4M
- IPO Year
- ALX N/A
- SANA 2021
- Fundamental
- Price
- ALX $244.39
- SANA $3.22
- Analyst Decision
- ALX
- SANA Strong Buy
- Analyst Count
- ALX 0
- SANA 5
- Target Price
- ALX N/A
- SANA $8.75
- AVG Volume (30 Days)
- ALX 42.2K
- SANA 4.2M
- Earning Date
- ALX 11-03-2025
- SANA 11-07-2025
- Dividend Yield
- ALX 7.37%
- SANA N/A
- EPS Growth
- ALX N/A
- SANA N/A
- EPS
- ALX 7.28
- SANA N/A
- Revenue
- ALX $218,089,000.00
- SANA N/A
- Revenue This Year
- ALX N/A
- SANA N/A
- Revenue Next Year
- ALX N/A
- SANA N/A
- P/E Ratio
- ALX $33.54
- SANA N/A
- Revenue Growth
- ALX N/A
- SANA N/A
- 52 Week Low
- ALX $184.76
- SANA $1.26
- 52 Week High
- ALX $260.84
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- ALX 64.45
- SANA 48.33
- Support Level
- ALX $232.45
- SANA $2.87
- Resistance Level
- ALX $238.24
- SANA $3.42
- Average True Range (ATR)
- ALX 5.30
- SANA 0.24
- MACD
- ALX 2.10
- SANA 0.03
- Stochastic Oscillator
- ALX 85.67
- SANA 50.56
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.